Looking beneath the surface of the CYP3A5 polymorphism

Pediatric Transplantation

Volumn 11, Issue 3, 2007, Pages 239-240

  Burckart, Gilbert J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

CYTOCHROME P450 CYP3A5 GENE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PROTEIN BINDING; EDITORIAL; GENE; GENOTYPE; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION;

ADOLESCENT; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 34147145908     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00688.x     Document Type: Editorial

References (16)

1. FERRARRESSO M, TIRELLI A, GRILLO P, MARTINA V, EDEFONTE A. Influence of Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 2006, Doi: 10.1111/j.1399-3046.2006.00688.
2. KUEHL P, ZHANG J, LIN Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383-391.
3. ZHENG H, WEBBER S, SCHUETZ E, et al. Cytochrome P4503A and TNF-α genotypes are associated with tacrolimus dosing in pediatric heart transplant patients. Hum Immunol 2002: 63 (Suppl. 1): S15.
4. ZHENG H, WEBBER S, ZEEVI A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1gene polymorphisms. Am J Transplant 2003: 3: 477-483.
5. BURCKART GJ, LIU XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006: 28: 23-30.
6. MACPHEE IA, FREDERICKS S, TAI T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation [see comment]. Am J Transplant 2004: 4: 914-919.
7. THOMPSON EE, KUTTAB-BOULOS H, WITONSKY D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004: 75: 1059-1069.
8. GIVENS RC, LIN YS, DOWLING AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003: 95: 1297-1300.
9. HO H, PINTO A, HALL SD, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005: 45: 294-298.
10. WANG J, ZEEVI A, MCCURRY K, et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 nonexpressors. Transpl Immunol 2006: 15: 235-240.
11. ZHENG HX, ZEEVI A, MCCURRY K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005: 14: 37-42.
12. GRINYO J, VANRENTERGHEM Y, NASHAN B, et al. Association of three polymorphisms with acute rejection after kidney transplantation: An exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the Caesar Study). Transplantation 2006: 82 (Suppl. 3): 410-411.
13. ASANO T, TAKAHASHI KA, FUJIOKA M, et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003: 13: 675-682.
14. HAUSER IA, SCHAEFFELER E, GAUER S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005: 16: 1501-1511.
15. YAMAUCHI A, IEIRI I, KATAOKA Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002: 74: 571-572.
16. MEISEL P, GIEBEL J, KUNERT-KEIL C, et al. MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clin Pharmacol Ther 2006: 79: 62-71.